Compound Dossiers

Small Molecule

A research small molecule commonly described as an NNMT inhibitor; human evidence and safety remain unclear.

Peptide (hGH Fragment)

A synthetic peptide derived from the C-terminal region of human growth hormone (hGH), discussed in metabolic/anti-obesity research with limited published clinical evidence.

Peptide (EPO-Derived)

An erythropoietin-derived peptide (cibinetide) studied in tissue-protective signaling; early clinical data exist in select indications.

Cosmetic Peptide

A cosmetic peptide (acetyl hexapeptide-8) used in topical formulations, with some randomized clinical evidence for wrinkle-related cosmetic endpoints.

Synthetic Peptide

A synthetic pentadecapeptide derived from human gastric juice proteins, investigated primarily in animal models for tissue repair and cytoprotection.

Melanocortin Receptor Agonist

An FDA-approved melanocortin receptor agonist studied in randomized Phase 3 trials for hypoactive sexual desire disorder (HSDD).

Amylin Analog

An investigational long-acting amylin analog studied alone and in combination with semaglutide for weight and cardiometabolic outcomes. FDA NDA filed December 2025 for CagriSema.

Growth Hormone Releasing Hormone Analog

A synthetic analog of growth hormone-releasing hormone (GHRH) designed for extended half-life, studied for growth hormone stimulation in research settings.

Small Molecule

A research compound discussed in neurotrophic/cognitive contexts; high-quality human evidence and safety are not established.

Peptide

A peptide historically discussed in sleep research; the endogenous biology, mechanism, and clinical relevance remain uncertain.

Peptide

A synthetic tetrapeptide (Ala-Glu-Asp-Gly) derived from pineal gland extract, studied over 25 years for geroprotective and neuroendocrine effects. Evidence includes in vitro, animal, and limited human studies showing antioxidant, neuro-protective, and antimutagenic effects. Not an approved medication.

Peptide (hGH Fragment)

A peptide fragment of human growth hormone (amino acids 176–191) studied in preclinical physiology; translation to human outcomes is not established.

Copper Peptide Complex

A naturally occurring copper-binding tripeptide studied for wound healing, skin regeneration, and anti-aging effects, primarily in topical applications.

Growth Hormone Secretagogue

A growth hormone secretagogue peptide (ghrelin receptor agonism) studied in humans and model systems; often discussed in research and anti-doping contexts.

Growth Hormone Secretagogue

A growth hormone–releasing peptide studied for multi-receptor activity and potential effects in model systems; not approved for clinical use.

Mitochondrial Peptide

An endogenous mitochondrial-derived peptide described as neuroprotective in experimental models; clinical translation and safety are not established.

Small Molecule

An oral small molecule ghrelin receptor agonist researched for growth hormone/IGF-1 axis effects; clinical use and safety are not established.

Growth Hormone Secretagogue

A selective growth hormone secretagogue peptide that stimulates GH release without significantly affecting cortisol or prolactin, often used in combination with GHRH analogs.

Unknown (Needs Verification)

A placeholder entry from an internal compounds sheet with unclear identity; nomenclature and primary sources need verification.

Peptide

A tripeptide (Lys-Pro-Val) discussed in inflammatory and gut-related preclinical research, including PepT1-mediated uptake in experimental models.

GLP-1 Receptor Agonist

A daily GLP-1 receptor agonist approved for Type 2 diabetes (Victoza) and weight management (Saxenda)., with RCT evidence for clinically meaningful weight loss.

Antimicrobial Peptide

An endogenous human cathelicidin antimicrobial peptide with antimicrobial and immunomodulatory roles; therapeutic use is experimental and context-dependent.

Cosmetic Peptide

A cosmetic peptide (palmitoyl pentapeptide-4) used in topical skincare, with small randomized clinical evidence for wrinkle-related cosmetic endpoints.

Melanocortin Peptide (α-MSH Analog)

An α-MSH analog approved for erythropoietic protoporphyria (EPP), with randomized trial evidence for reduced phototoxicity-related outcomes. EMA adolescent indication withdrawn April 2024.

Melanocortin Peptide

A melanocortin peptide discussed for pigmentation and other effects; not approved for clinical use and associated with safety concerns in reports.

Mitochondria-Derived Peptide

A mitochondria-derived peptide studied in preclinical models for metabolic regulation; evidence is primarily preclinical with ongoing research.

Endogenous Cofactor

A central cellular redox cofactor; research often focuses on NAD+ metabolism and precursors, with varied evidence and unclear clinical translation.

Peptide (Spadin Analog)

A spadin-derived peptide reported to inhibit the TREK-1 potassium channel and show antidepressant-like effects in rodent models; clinical evidence is not established.

Triple Incretin Agonist

An investigational triple agonist (GIP/GLP-1/glucagon) that achieved 28.7% weight loss in Phase 3 (TRIUMPH-4); currently in registrational trials with first successful results reported Dec 2025.

Neuropeptide Analog

A peptide analog explored in anxiolytic contexts in some regions; much of the accessible clinical literature is regionally concentrated.

GLP-1 Receptor Agonist

A potent GLP-1 receptor agonist FDA-approved for Type 2 diabetes (Ozempic/Rybelsus) and chronic weight management (Wegovy), with extensive cardiovascular outcomes data.

Neuropeptide Analog

A peptide analog discussed in neurocognitive contexts in some regions; much of the accessible clinical literature is regionally concentrated.

Peptide (GHRH Analog)

A growth hormone–releasing hormone (GHRH) 1–29 analog studied for stimulating growth hormone secretion; evidence and risks depend on indication and context.

Cosmetic Peptide

A cosmetic peptide (acetyl octapeptide-3) used in topical formulations; clinical evidence exists but is often multi-ingredient and formulation-specific.

Mitochondrial Peptide

A mitochondria-targeting peptide (elamipretide) investigated in primary mitochondrial myopathy and other indications, with randomized trial evidence in select populations.

Regenerative Peptide

A synthetic fragment of thymosin beta-4, investigated in animal models for wound healing, tissue repair, and anti-inflammatory effects.

GHRH Analog

An FDA-approved growth hormone–releasing hormone (GHRH) analog used in HIV-associated lipodystrophy; studied for effects on visceral adiposity and metabolic markers.

Small Molecule

A monoamine reuptake inhibitor investigated in obesity and neuropsychiatric contexts; benefit-risk depends on dose, population, and indication. COFEPRIS approved in Mexico (2023).

Thymic Peptide Extract

A thymus-derived polypeptide mixture discussed as immunomodulatory; composition and evidence base vary by product and region.

Thymosin Peptide

An immunomodulatory peptide studied across infectious and inflammatory contexts; evidence quality varies by indication and study design.

Thymosin Peptide

A naturally occurring peptide studied for actin-binding and tissue repair biology; clinical translation remains limited and indication-dependent.

Dual Incretin Agonist

A dual GIP and GLP-1 receptor agonist FDA-approved for Type 2 diabetes (Mounjaro) and chronic weight management (Zepbound). Showing superior efficacy to semaglutide in head-to-head trials.